BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 35962190)

  • 1. Virus-like particle vaccinology, from bench to bedside.
    Mohsen MO; Bachmann MF
    Cell Mol Immunol; 2022 Sep; 19(9):993-1011. PubMed ID: 35962190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-like Particle Vaccines and Platforms for Vaccine Development.
    Kheirvari M; Liu H; Tumban E
    Viruses; 2023 May; 15(5):. PubMed ID: 37243195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and future directions of fish vaccines employing virus-like particles.
    Jeong KH; Kim HJ; Kim HJ
    Fish Shellfish Immunol; 2020 May; 100():49-57. PubMed ID: 32130976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major findings and recent advances in virus-like particle (VLP)-based vaccines.
    Mohsen MO; Zha L; Cabral-Miranda G; Bachmann MF
    Semin Immunol; 2017 Dec; 34():123-132. PubMed ID: 28887001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
    Garg H; Sedano M; Plata G; Punke EB; Joshi A
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-like particles as powerful vaccination strategy against human viruses.
    Hadj Hassine I; Ben M'hadheb M; Almalki MA; Gharbi J
    Rev Med Virol; 2024 Jan; 34(1):e2498. PubMed ID: 38116958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites.
    Chu KB; Quan FS
    Curr Top Microbiol Immunol; 2021; 433():77-106. PubMed ID: 33650036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and characterization of virus-like particles: a review.
    Zeltins A
    Mol Biotechnol; 2013 Jan; 53(1):92-107. PubMed ID: 23001867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering virus-like particles as vaccine platforms.
    Frietze KM; Peabody DS; Chackerian B
    Curr Opin Virol; 2016 Jun; 18():44-9. PubMed ID: 27039982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic biology for bioengineering virus-like particle vaccines.
    Charlton Hume HK; Vidigal J; Carrondo MJT; Middelberg APJ; Roldão A; Lua LHL
    Biotechnol Bioeng; 2019 Apr; 116(4):919-935. PubMed ID: 30597533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus like particle-based vaccines against emerging infectious disease viruses.
    Liu J; Dai S; Wang M; Hu Z; Wang H; Deng F
    Virol Sin; 2016 Aug; 31(4):279-87. PubMed ID: 27405928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel expression of coat proteins from thermophilic bacteriophage ΦIN93 and evaluation for assembly into virus-like particles.
    Zhai L; Anderson D; Bruckner E; Tumban E
    Protein Expr Purif; 2021 Nov; 187():105932. PubMed ID: 34214599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of plant viruses and virus-like particles for the creation of novel vaccines.
    Balke I; Zeltins A
    Adv Drug Deliv Rev; 2019 May; 145():119-129. PubMed ID: 30172923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity.
    Joe CCD; Chatterjee S; Lovrecz G; Adams TE; Thaysen-Andersen M; Walsh R; Locarnini SA; Smooker P; Netter HJ
    Vaccine; 2020 May; 38(22):3892-3901. PubMed ID: 32284273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
    Mulder AM; Carragher B; Towne V; Meng Y; Wang Y; Dieter L; Potter CS; Washabaugh MW; Sitrin RD; Zhao Q
    PLoS One; 2012; 7(4):e33235. PubMed ID: 22493667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
    Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
    Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.